INCREMENTAL BENEFIT OF OPEN-LABEL CERTOLIZUMAB PEGOL plus MTX IN RHEUMATOID ARTHRITIS (RA) PATIENTS FOLLOWING DOUBLE-BLIND PLACEBO plus MTX TREATMENT OUT TO 2 YEARS

Author(s):
Combe, B.; Schwartzman, S.; Massarotti, E.; Keystone, E.C.; Luijtens, K.; Heijde, D. van der
Published
2010
Publication type
Other
Date issued
2010-04-30
Language
English
hdl
1887/111642